Fast Market Research announces the availability of the new Global Markets Direct report, "Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2017", on their comprehensive research portal

Boston, MA -- (SBWire) -- 07/06/2017 --Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 33 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The latest report Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2017, outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Get More Details on this Report and a Full Table of Contents at Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2017

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 2, 5, 8, 9, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Immunology, Central Nervous System, Gastrointestinal, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Respiratory and Undisclosed which include indications Solid Tumor, Melanoma, Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ovarian Cancer, Pancreatic Cancer, Tenosynovial Giant Cell Tumor, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Breast Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Papillary Thyroid Cancer, Pigmented Villonodular Synovitis, Bladder Cancer, Colorectal Cancer, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST), Inflammation, Metastatic Colorectal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bone Metastasis, Colon Cancer, Crohn's Disease (Regional Enteritis), Epithelial Ovarian Cancer, Follicular Thyroid Cancer, Lung Adenocarcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Thyroid Cancer, Acral Lentiginous Melanoma, Acute Ischemic Stroke, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaplastic Thyroid Cancer, Angiosarcoma, Asthma, Autoimmune Disorders, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Depression, Dysthymia, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Endometrial Cancer, Ewing Sarcoma, Fibrosarcoma, Gallbladder Cancer, Germ Cell Tumors, Gliosarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Lung Cancer, Malignant Ascites, Malignant Mesothelioma, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Biliary Tract Cancer, Metastatic Liver Cancer, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neuroinflammation, Non-Small Cell Lung Carcinoma, Osteolysis, Osteosarcoma, Pain, Pancreatic Ductal Adenocarcinoma, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Pheochromocytoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Prostate Cancer, Refractory Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Renal Failure, Rhabdomyosarcoma, Rheumatoid Arthritis, Salivary Gland Cancer, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Unspecified, Urticaria Pigmentosa (Mastocytosis, Mastocytoma) and Uveal Melanoma.

Companies Mentioned in this Report: AB Science SA, Amgen Inc, Array BioPharma Inc, BCI Pharma, Bristol-Myers Squibb Company, Cielo Therapeutics Inc, CrystalGenomics Inc, CTI BioPharma Corp, Deciphera Pharmaceuticals LLC, Eli Lilly and Company, Elsalys Biotech SAS, F. Hoffmann-La Roche Ltd, Hutchison China MediTech Ltd, Ignyta Inc, Johnson & Johnson, Nerviano Medical Sciences Srl, Novartis AG, Pfizer Inc, Plexxikon Inc, Redx Pharma Plc, SignalChem Lifesciences Corp, Syndax Pharmaceuticals Inc

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2017
-Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2016
-Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2016
-High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2017
-Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017